Fig. 2: Radiological and pathological outcomes of participants. | Nature Communications

Fig. 2: Radiological and pathological outcomes of participants.

From: Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial

Fig. 2

a Waterfall plots of radiological regression of all participants’ TLD after neoadjuvant Aumolertinib treatment. b Waterfall plots of surgical treated pathological regression. TLD target-lesions dimension, SD stable disease, PR partial response, MPR major pathological response, pCR complete pathological response. Source data are provided as a Source Data file.

Back to article page